The Board of Directors of Laurus Labs at their meeting held on April 30, 2026, approved several significant corporate decisions including director appointments and retirement, investment in joint venture, and voluntary closure of its German subsidiary. The meeting commenced at 2.00 p.m. and concluded at 3.00 p.m.

Director Appointments and Retirement

On the recommendation of the Nomination and Remuneration Committee, the Board approved and recommended to shareholders the appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454) and Ms. Sutapa Banerjee (DIN: 02844650) as Independent Directors for a term of five consecutive years effective from July 02, 2026. Both appointees are not related to any Directors or Key Managerial Personnel of the Company and are not debarred from holding the office of Director.

Dr. Shekhar Chintamani Mande is a structural and computational biologist, distinguished professor at Savitribai Phule Pune University, and former Director General of CSIR. He was awarded the Shanti Swarup Bhatnagar Prize in 2005 and currently serves as an Independent Director on the board of Tata Steel Limited. Ms. Sutapa Banerjee has over three decades of experience in financial services, including leadership roles at ANZ Grindlays, ABN AMRO, and Ambit Private Wealth. She was voted one of the 'Top 20 Global Rising Stars of Wealth Management' by the Institutional Investor Group in 2007.

The Board also took note of the retirement of Mrs. Aruna Bhinge (DIN: 07474950) as Independent Director effective from close of business hours on July 6, 2026, after completing her second term from July 7, 2021 to July 6, 2026.

Investment in KRKA Pharma Joint Venture

The Board approved an investment of up to EUR 9,800,000 in KRKA Pharma Private Limited, a joint venture incorporated in April 2024. The co-venturer, KRKA d.d., Novo mesto, Slovenia, will also invest approximately EUR 10,200,000. The existing 51:49 shareholding ratio between KRKA d.d. and Laurus Labs Limited will remain unchanged.

KRKA Pharma has an authorised share capital of INR 370,00,00,000 divided into 37,00,00,000 equity shares of INR 10 each, and paid-up share capital of INR 315,00,00,000 divided into 31,50,00,000 equity shares of INR 10 each. The turnover for 2025-26 was INR 10.47 million. The funds will be utilised for KRKA's capital expenditure plan to establish a manufacturing facility.

Closure of German Subsidiary

The Board approved the voluntary closure of Laurus Generics GmbH, a step-down wholly owned subsidiary in Germany, in accordance with applicable German laws. The subsidiary reported nil revenue for the financial year ended March 31, 2026, and maintained a negative net worth of EUR 10,53,091.

The closure will not have any material impact on the company or its financials. The process will be completed subject to regulatory approvals in Germany, and the company will inform the exchanges upon completion of the closure formalities.

Laurus labs has completed its quarterly regulatory filing by submitting the mandatory certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The submission was made to both major stock exchanges on April 15, 2026.

Regulatory Compliance Details

The company submitted the required documentation to fulfill its obligations under SEBI regulations. The certificates were issued by KFin Technologies Limited, which serves as the Registrar and Share Transfer Agent for Laurus Labs Limited.

Stock Exchange Notifications

The certificates were submitted to both primary stock exchanges where the company's shares are traded:

• BSE Limited: Submitted to Corporate Relations Department at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai
• National Stock Exchange of India Limited: Submitted to Listing Department at Exchange Plaza, Bandra Kurla Complex, Mumbai

Depository Certifications

KFin Technologies Limited issued separate certificates to both major depositories on April 2, 2026:

Certificate Confirmation

The certificates confirm that all details of securities dematerialized and rematerialized during the quarter ended March 31, 2026 have been properly furnished to all stock exchanges where Laurus Labs Limited shares are listed. This certification ensures compliance with SEBI (Depositories and Participants) Regulations 2018.

The regulatory filing demonstrates the company's commitment to maintaining transparency and adhering to all prescribed compliance requirements as mandated by securities market regulations.